Evaluation of Mesenchymal Stromal Cell Therapy for Post-Operative Recovery in Frail Elderly Patients Following Hip Fracture Surgery

The primary objective of this study is to evaluate the efficacy of **mesenchymal stromal cell therapy** in enhancing post-operative recovery following hip fracture surgery in frail elderly patients. This is clinically relevant as hip fractures in this population are associated with significant morbidity and mortality, and improving recovery outcomes can substantially impact patient quality of life and healthcare resource utilization.

The clinical trial focuses on **post-operative recovery** after hip fracture surgery in frail elderly patients. The study population includes both male and female participants, with an age range categorized as 65 years and older. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants involved in the study. Participants were selected without any specific mention of lifestyle considerations such as diet, physical activity, or habits. Key inclusion or exclusion criteria have not been disclosed by the sponsor.

The clinical trial is designed to evaluate the efficacy of **mesenchymal stromal cell therapy** in the rehabilitation of frail elderly patients following hip fracture surgery. This study is a Phase 3, randomized, double-blind, controlled trial, which aims to provide robust data on the therapeutic potential of the intervention. The trial is scheduled to commence recruitment on January 1, 2025, and is expected to conclude by December 31, 2027. Participants will be involved in the study for a duration that aligns with the trial's timeline, with specific visit schedules and assessments outlined to ensure comprehensive data collection.

The sequence of study visits begins with an inclusion visit, where potential participants undergo a screening process to determine eligibility based on predefined criteria. Following successful inclusion, participants will be randomized into either the treatment or control group. Throughout the trial, follow-up visits will be conducted at regular intervals to monitor the participants' progress, assess the primary and secondary endpoints, and ensure adherence to the study protocol. The end-of-study visit will mark the completion of the trial for each participant, during which final assessments will be conducted to evaluate the outcomes of the intervention.

Participant involvement is expected to last until the end of the trial, unless specific conditions necessitate early termination. Such conditions may include adverse events, withdrawal of consent, or any other factors that compromise the safety or well-being of the participant. The trial's methodology and design are structured to maintain scientific rigor and ensure the reliability of the results, contributing valuable insights into the management of post-operative recovery in this vulnerable patient population.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 3 study, indicating it is focused on confirming the effectiveness of the intervention, monitoring side effects, and collecting information that will allow the intervention to be used safely. The trial is scheduled to commence recruitment on January 1, 2025, with an estimated completion date of December 31, 2027. Although specific primary and secondary endpoints are not detailed, Phase 3 trials typically involve the use of validated scales, laboratory tests, and patient-reported outcomes to measure efficacy. These assessments are conducted at predetermined timepoints throughout the trial to ensure comprehensive data collection and analysis. The trial's methodology is aligned with standard clinical practices to ensure the reliability and validity of the efficacy data collected.